Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, 3-Arm, Open-Label, Phase Ⅱa Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma

NCT03033524 is registered in ClinicalTrials.gov with PharmAbcine as lead sponsor.

NCT NCT03033524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03033524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, 3-Arm, Open-Label, Phase Ⅱa Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma
Lead sponsor
PharmAbcine
Phase
Phase 2
Overall status
Completed
Start date
February 4, 2016
Completion date
June 2, 2017
Enrollment
12 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma